Hsbc Holdings PLC Has $9.14 Million Position in Xenon Pharmaceuticals Inc. $XENE

Hsbc Holdings PLC increased its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 24.6% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 151,474 shares of the biopharmaceutical company’s stock after buying an additional 29,916 shares during the quarter. Hsbc Holdings PLC’s holdings in Xenon Pharmaceuticals were worth $9,143,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Danske Bank A S bought a new stake in Xenon Pharmaceuticals in the 3rd quarter valued at approximately $32,000. Kestra Advisory Services LLC acquired a new stake in shares of Xenon Pharmaceuticals in the fourth quarter valued at approximately $33,000. Osaic Holdings Inc. raised its holdings in shares of Xenon Pharmaceuticals by 541.4% in the second quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 1,034 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in shares of Xenon Pharmaceuticals in the fourth quarter worth $43,000. Finally, Rockefeller Capital Management L.P. lifted its position in shares of Xenon Pharmaceuticals by 450.0% in the fourth quarter. Rockefeller Capital Management L.P. now owns 1,100 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 900 shares in the last quarter. Institutional investors and hedge funds own 95.45% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on XENE. Wall Street Zen raised shares of Xenon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 1st. JPMorgan Chase & Co. boosted their price target on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 27th. HC Wainwright restated a “buy” rating and set a $74.00 price objective on shares of Xenon Pharmaceuticals in a research note on Monday, August 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a report on Monday, July 6th. Finally, Royal Bank Of Canada lowered their target price on Xenon Pharmaceuticals from $82.00 to $81.00 and set an “outperform” rating on the stock in a research report on Friday, August 7th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $77.13.

Xenon Pharmaceuticals Trading Down 1.0%

NASDAQ:XENE opened at $58.98 on Thursday. Xenon Pharmaceuticals Inc. has a 1-year low of $35.60 and a 1-year high of $72.66. The firm has a fifty day simple moving average of $63.51 and a 200 day simple moving average of $57.48. The stock has a market capitalization of $5.70 billion, a PE ratio of -12.44 and a beta of 0.61.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.05. During the same quarter last year, the company earned ($1.07) EPS. On average, equities analysts predict that Xenon Pharmaceuticals Inc. will post -4.73 earnings per share for the current fiscal year.

Insider Transactions at Xenon Pharmaceuticals

In other news, insider Christopher Kenney sold 7,068 shares of the company’s stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $60.25, for a total value of $425,847.00. Following the sale, the insider directly owned 2 shares of the company’s stock, valued at approximately $120.50. This represents a 99.97% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Steven Gannon sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $64.06, for a total transaction of $640,600.00. Following the completion of the sale, the director owned 1,870 shares of the company’s stock, valued at $119,792.20. This trade represents a 84.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 2.91% of the company’s stock.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.